Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable

Oncology Reports

Volumn 26, Issue 1, 2011, Pages 49-54

  Suda, Tetsuji ^a   Yoshihara, Mitsuyo ^a   Nakamura, Yoshiyasu ^a   Sekiguchi, Hironobu ^a   Godai, Ten I ^a   Sugano, Nobuhiro ^a   Tsuchida, Kazuhito ^a   Shiozawa, Manabu ^a   Sakuma, Yuji ^a   Tsuchiya, Eiju ^a   Kameda, Yoichi ^a   Akaike, Makoto ^a   Matsukuma, Shoichi ^a   Miyagi, Yohei ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Colorectal cancer; Gene amplification; MDM2; MDM4 (MDMX); p53

Indexed keywords

PROTEIN MDMX; PROTEIN P53;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CASE REPORT; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE IDENTIFICATION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MDM4 GENE; ONCOGENE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79955809584     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1270     Document Type: Article

References (33)

1. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994. (Pubitemid 24289415)
2. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T and Gebbia N; TP53-CRC Collaborative Study Group: The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment J Clin Oncol 23: 7518-7528, 2005. (Pubitemid 46291815)
3. Godai TI, Suda T, Sugano N, Tsuchida K, Shiozawa M, Sekiguchi H, Sekiyama A, Yoshihara M, Matsukuma S, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M and Miyagi Y: Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer 9: 420, 2009.
4. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489-499, 2009.
5. McDermott U, Longley DB and Johnston PG: Molecular and biochemical markers in colorectal cancer. Ann Oncol 13: 235-245, 2002. (Pubitemid 35363779)
6. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
7. Fang S, Jensen JP, Ludwig RL, Vousden KH and Weissman AM: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275: 8945-8951, 2000. (Pubitemid 30180252)
8. Momand J, Jung D, Wilczynski S and Niland J: The MDM2 gene amplification database. Nucleic Acids Res 26: 3453-3459, 1998.
9. Toledo F and Wahl GM: Regulating the p53 pathway: in vitro hypotheses, in vivo Veritas. Nat Rev Cancer 6: 909-923, 2006. (Pubitemid 44862676)
10. Forslund A, Zeng Z, Qin LX, Rosenberg S, Ndubuisi M, Pincas H, Gerald W, Notterman DA, Barany F and Paty PB: MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers. Mol Cancer Res 6: 205-211, 2008. (Pubitemid 351342408)
11. Sugano N, Suda T, Godai TI, Tsuchida K, Shiozawa M, Sekiguchi H, Yoshihara M, Matsukuma S, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M and Miyagi Y: MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis. Genes Chromosomes Cancer 49: 620-629, 2010.
12. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt W, Hateboer G, van der Eb AJ and Jochemsen AG: MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 15: 5349-5357, 1996. (Pubitemid 26336217)
13. Jackson MW and Berberich SJ: MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 20: 1001-1007, 2000. (Pubitemid 30044237)
14. Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, Saville MK and Jochemsen AG: Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep 2: 1029-1034, 2001. (Pubitemid 33130611)
15. Sharp DA, Kratowicz SA, Sank MJ and George DL Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 274: 38189-38196, 1999. (Pubitemid 30026893)
16. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A and Ohtsubo M: MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 447: 5-9, 1999. (Pubitemid 29134936)
17. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G and Yuan ZM: Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 277: 19251-19254, 2002. (Pubitemid 34967428)
18. Linares LK, Hengstermann A, Ciechanover A, Müller S and Scheffner M: HdmX stimulates Hdm2-mediated ubiquitination and degradation of P53. Proc Natl Acad Sci USA 100: 12009-12014, 2003. (Pubitemid 37271506)
19. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG and Dyer MA: Inactivation of the p53 pathway in retinoblastoma. Nature 444: 61-66, 2006.
20. Hamilton SR and Aaltonen LA: WHO Qassification of Tumors: Pathology and Genetics of Tumours of Digestive System. IARC Press, Lyon, p320, 2000.
21. Sobin LH and Wittekind C: International Union Against Cancer (UICC) TNM Classification of Malignant Tumors. 6th edition, Wiley-Liss, New York, P272, 2002.
22. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, Kameda Y, Tsuchiya E and Miyagi Y: Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 128: 100-108, 2007. (Pubitemid 47121721)
23. Kuismanen SA, Moisio AL, Schweizer P, Truninger K, Salovaara R, Arola J, Butzow R, Jiricny J, Nyström-Lahti M and Peltomäki P: Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol 160: 1953-1958, 2002.
24. Giannini G, Rinaldi C, Ristori E, Ambrosini MI, Cerignoli F, Viel A, Bidoli E, Berni S, D'Amati G, Scambia G, Frati L, Screpanti I and Gulino A: Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with micro satellite instability. Oncogene 23: 2640-2647, 2004 (Pubitemid 38586317)
25. Lengauer C, Green ED and Cremer T: Fluorescence in situ hybridization of YAC clones after Alu-PCR amplification. Genomics 13: 826-828, 1992.
26. Rallapalli R, Strachan G, Cho B, Mercer WE and Hall DJ: A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J Biol Chem 274: 8299-8308, 1999.
27. Pereg Y, Shkedy D, de Graaf P, Meulmeester E, Edelson-Averbukh M, Salek M, Biton S, Teunisse AF, Lehmann WD, Jochemsen AG and Shiloh Y: Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci USA 102: 5056-5061, 2005.
28. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A, Helin K, Pelicci PG, Jochemsen AG and Marine JC: Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24: 5835-5843, 2004. (Pubitemid 38787968)
29. Arjona D, Bello MJ, Alonso ME, Isla A, De Campos JM, Vaquera J, Sarasa JL, Gutierrez M and Rey A: Real-time quantitative PCR analysis of regions involved in gene amplification reveals gene overdose in low-grade astrocytic gliomas. Diagn Mol Pathol 14: 224-229, 2005. (Pubitemid 41734998)
30. Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A, Teunisse A, Migliorini D, Kitabayashi I, Marine JC, Prives C, Shiloh Y, Jochemsen AG and Taya Y: DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol 25: 9608-9620, 2005. (Pubitemid 41507859)
31. LeBron C, Chen L, Gilkes DM and Chen J: Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J 25: 1196-1206, 2006.
32. Gilkes DM, Pan Y, Coppola D, Yeatman T, Reuther GW and Chen J: Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol 28: 1999-2010, 2008.
33. Jernvall P, Mäkinen MJ, Karttunen TJ, Mäkelä J and Vihko P: Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer 35: 197-201, 1999. (Pubitemid 29136767)